Vaccination News

A review of the CDC’s performance during the COVID-19 pandemic found that the agency was slow to share science and data, struggled to develop practical policies and fell short of prioritizing public health communications.

The public health and national emergencies declared by the United States in the early days of the COVID-19 pandemic expire at the end of the day on May 11.

GSK’s Arexvy, a vaccine against respiratory syncytial virus, was approved by the FDA and is expected to be available this fall for adults aged 60 years and older.

WHO recently ended the COVID-19 global public health emergency — and the United States will soon lift its own emergency declarations — but questions about vaccination, especially for children, persist.

Last April, Rochelle P. Walensky, MD, MPH, requested an internal and external review of the CDC’s performance during the COVID-19 pandemic.

U.S. adults who reported negative health care experiences because of discrimination based on their race or ethnicity were less likely to be vaccinated against COVID-19, a study found.

WHO said Friday that the COVID-19 pandemic no longer constitutes a global public health emergency of international concern, citing reduced risks to human health driven by high population-level immunity and vaccination.

The FDA on Wednesday approved the world’s first vaccine against respiratory syncytial virus, which followed years of failed attempts by scientists to develop one.

This week, Healio provided live coverage of the Pediatric Academic Societies Meeting, an annual collaboration between the AAP, Academic Pediatrics Association, American Pediatric Society and the Society for Pediatric Research.

The White House announced that it will end COVID-19 vaccine requirements for federal employees and international air travelers on May 11, the same day the public health and national emergencies for the pandemic are scheduled to end.